Pfizer und BioNTech veröffentlichen weitere Daten aus Phase-3-Studie: Bis zu 6 Monate nach zweiter Impfung hohe Wirksamkeit und keine schweren Sicherheitsbedenken des COVID-19-Impfstoffs bestätigt

NEXT STORY
Journey Medical Corporation Enters into a Definitive Agreement with Dermira, Inc., a Wholly-Owned Subsidiary of Eli Lilly and Company, to Acquire QBREXZA®
PREV STORY
SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b Combination Study Evaluating Nirogacestat and Janssen’s BCMA Bispecific Antibody Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Immunotech Laboratories, Inc. Receives Invitation to the 2018 Asia-Pacific Precision Medicine Forum

Monrovia, CA, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Immunotech Laboratories, Inc. f/k/a Eco-Petroleum Solutions, ...

author_avatar
NASDAQ Market News

Japanese In-Vitro Diagnostics (IVD) Industry 2020-2026 with Analysis on Abbott Labs, Danaher, bioMerieux, Roche Diagnostics and BD

author_avatar
NASDAQ Market News

A Post-hoc Analysis of Phase 3 Study Demonstrates Baseline Factors Associated with Visual Acuity and Anatomical Outcomes of Samsung Bioepis’ BYOOVIZ™ (Ranibizumab) in nAMD at the EURETINA 2021

author_avatar
NASDAQ Market News